Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

No effect of triheptanoin on exercise performance in McArdle disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Responsiveness of outcome measures in myotonic dystrophy type 1

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Early prediction of phenotypic severity in Citrullinemia Type 1

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phenotypic Spectrum of α-Dystroglycanopathies Associated With the c.919T>a Variant in the FKRP Gene in Humans and Mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Editorial: Remaining diagnostic issues and start of a treatment era for muscle diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: To study if treatment with triheptanoin, a 7-carbon triglyceride, improves exercise tolerance in patients with McArdle disease. McArdle patients have a complete block in glycogenolysis and glycogen-dependent expansion of tricarboxylic acid cycle (TCA), which may restrict fat oxidation. We hypothesized that triheptanoin metabolism generates substrates for the TCA, which potentially boosts fat oxidation and improves exercise tolerance in McArdle disease. Methods: Double-blind, placebo-controlled, crossover study in patients with McArdle disease completing two treatment periods of 14 days each with a triheptanoin or placebo diet (1 g/kg/day). Primary outcome was change in mean heart rate during 20 min submaximal exercise on a cycle ergometer. Secondary outcomes were change in peak workload and oxygen uptake along with changes in blood metabolites and respiratory quotients. Results: Nineteen of 22 patients completed the trial. Malate levels rose on triheptanoin treatment versus placebo (8.0 ± SD2.3 vs. 5.5 ± SD1.8 µmol/L, P < 0.001), but dropped from rest to exercise (P < 0.001). There was no difference in exercise heart rates between triheptanoin (120 ± SD16 bpm) and placebo (121 ± SD16 bpm) treatments. Compared with placebo, triheptanoin did not change the submaximal respiratory quotient (0.82 ± SD0.05 vs. 0.84 ± SD0.03), peak workload (105 ± SD38 vs. 102 ± SD31 Watts), or peak oxygen uptake (1938 ± SD499 vs. 1977 ± SD380 mL/min). Interpretation: Despite increased resting plasma malate with triheptanoin, the increase was insufficient to generate a normal TCA turnover during exercise and the treatment has no effect on exercise capacity or oxidative metabolism in patients with McArdle disease.

Original languageEnglish
JournalAnnals of Clinical and Translational Neurology
Volume6
Issue number10
Pages (from-to)1949-1960
Number of pages12
ISSN2328-9503
DOIs
Publication statusPublished - Oct 2019

ID: 58348261